Erdosteine

• UNSPSC Description:

  Erdosteine inhibits lipopolysaccharide (LPS)-induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].

• Target Antigen:

  Bacterial; NF-κB

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;NF-κB

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Infection; Metabolic Disease; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Erdosteine.html

• Purity:

  99.83

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : 6.67 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CSCC(NC(CCS1)C1=O)=O

• Molecular Weight:

  249.31

• References & Citations:

  [1]Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39(4):1573-81.|[2]Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26(7):433-8.|[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  84611-23-4